11/2/2012

R Biomedical and StemCells agreed to jointly develop cell lines and reagents for use in human induced pluripotent stem cell studies aimed at regenerative medicine. The partners said they have commercialized their first product together, an "ultra-primary" human fibroblast cell line designed for iPS cell generation.

Related Summaries